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This session not only described several poly(ADP-ribose)polymerase (PARP) inhibitors but also included talks on
the science of nuclear excision repair, an oxidized glutathi-
one, and a heat shock protein (HSP) 90 inhibitor.
SUMMARY OF PRESENTATIONS
Science of Nuclear Excision Repair
Dr. George Simon opened the session by presenting the
science of nuclear excision repair. He reviewed preclinical
data, including evidence that apoptosis increases in cell lines
exposed to cisplatin when excision repair cross-complemen-
tation group 1 (ERCC1) siRNA is added. He also reviewed
clinical data from the International Adjuvant Lung Trial, in
which improved survival with adjuvant cisplatin-based che-
motherapy was restricted to tumors with low ERCC1.1 He
then focused on trials that designed to tailor therapy to repair
genes.
The Spanish Customized Adjuvant Treatment trial ran-
domly assigns postresection patients with positive N1 or N2
nodes to docetaxel cisplatin or an experimental arm. Based
on data correlating higher breast cancer 1 (BRCA1) mRNA
levels with cisplatin resistance and docetaxel sensitivity,2 the
experimental arm assigns treatment by quartile expression for
BRCA1 (lowest: gemcitabine  cisplatin; 2–3: docetaxel 
cisplatin; and highest: docetaxel).
The TAilored post-Surgical Therapy in Early-stage
NSCLC (TASTE) trial randomizes postsurgical patients to
cisplatin  pemetrexed or an experimental arm. In the
experimental arm, mutations in the epidermal growth fac-
tor receptor (EGFR) lead to treatment with erlotinib,
whereas treatment for EGFR wild-type patients are as-
signed based on ERCC1 status (cisplatin  pemetrexed
versus observation).
He then discussed the MADe IT Trail, in which patients
with metastatic disease were assigned treatment regimen
based on ERCC1 and ribonucleotide reductase M1 (RRM1)
levels (Figure 1). Outcomes in this trial exceeded selected
historical controls, and the difference was more apparent for
survival than for progression-free survival.3,4 Dr. Simon hy-
pothesized that up-regulation of ERCC1 or RRM1 in re-
sponse to therapy could alter tumor biology toward a more
indolent phenotype. A phase III trial has been designed to
randomize patients to the MADe IT algorithm or gemcitabine
carboplatin.
NOV-002 Phase III Trial Results
Lynch et al. discussed data from a phase III open-
labeled trial of carboplatin and paclitaxel  NOV-002. This
agent alters cellular redox status and alters the activity of
redox-sensitive proteins. This drug was marketed in Russia
based on a randomized phase II trial of 68 patients who
showed a 1-year survival of 17% for chemotherapy alone,
compared with 63% for chemotherapy  NOV-002. A phase
I/II study in the United States showed a response rate of 33%
for chemotherapy alone as opposed to 69% for chemotherapy
plus NOV-002. This 907-patient study in frontline patients
with stage IIIB/IV NSCLC using a carboplatin  paclitaxel
backbone completed accrual in March 2008. Unfortunately,
the primary end point of overall survival improvement was
not met (as was presented at the recently concluded meeting
of the American Society of Clinical Oncology), and the future
of the drug is uncertain.
IPI-504
Dr. Lecia Sequist discussed IPI-504 (retaspimycin hy-
drochloride), an HSP-90 inhibitor. As will be discussed in
more detail in this issue, HSP90 is being extensively evalu-
ated as a target for therapy, based on its role as a chaperone
for multiple proteins with important functions in oncogenesis
(including human epithelial growth factor receptor 2 (HER2),
EML4-anaplastic lymphoma kinase, and mutant EGFR). The
agent is a potent, water-soluble agent that interconverts with
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FIGURE 1. The algorithm.
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17-AAG. In a clinical trial in patients with tissue available
who failed a previous EGFR tyrosine kinase inhibitor (TKI),
the toxicity profile seemed favorable. No responses were seen
in 19 patients with EGFR mutant tumors, but 4 of 28 (14%)
patients with WT EGFR experienced a partial response.5
PARP Inhibitors
Poly-ADP ribosylation is a posttranslational modifica-
tion that covalently adds varying numbers of ADP residues to
proteins. PARP-1 is the most ubiquitous member of the
PARP family and is activated by DNA strand breaks. PARP
inhibition leads to the accumulation of single-strand DNA
breaks, and recent data demonstrated clinical activity of
PARP inhibitors, particularly in the setting of other errors in
DNA repair pathways. Dr. Ramaswamy Govindan briefly
discussed a group of agents that are not being actively
pursued in development at this time, but the bulk of the
discussion revolved around four compounds discussed below.
Dr. Shapiro discussed a phase I study of AZD2281
(KU0059436, olaparib). After maximum tolerated dose was
determined to be 400 mg twice daily, a cohort of patients with
germline BRCA mutations were enrolled. Approximately
half of BRCA mutant patients (breast, ovarian, and prostate
cancer) derived benefit, defined by radiographic or tumor
marker response or stable disease for at least 4 months.6 More
than 1/3 of patients in two single-agent phase II studies in
BRCA-deficient breast and ovarian cancer met prespecified
criteria for clinical benefit. Active clinical trials at the time of
the meeting included studies in triple-negative breast, ovar-
ian, gastric, and colon cancer.
Dr. Patricia LoRusso discussed the PARP inhibitor
ABT 888, describing it as a potent, orally bioavailable agent
that crosses the blood brain barrier. Preclinical data were
shown demonstrating potentiation of the effects of radiation,
carboplatin, and temozolamide.7 In a phase I clinical trial,
PARP inhibition was assessed in peripheral blood mononu-
clear cells at several time points and biopsy specimens
pretreatment and 3 to 6 hours after treatment. High-level
PARP inhibition was demonstrated in both the peripheral
blood mononuclear cells and the tumor. Further clinical
investigation is being pursued along with several different
chemotherapeutics.
Dr. Bradley discussed BSI-201, an intravenous small
molecule inhibitor of PARP1 and other NAD binding
enzymes. The agent is lipophilic and crosses the blood-brain
barrier. Data demonstrating disparate levels of PARP1 (but
not PARP2) between normal tissue and certain tumors were
shown. A phase II study in triple-negative breast cancer
demonstrated improved survival with a favorable safety pro-
file.8 The clinical development plan for the agent was out-
lined, including a phase III trial with a carboplatin  gem-
citabine backbone in squamous cell carcinoma of the lung.
Dr. Maurizio Voi discussed PF-01367338 (formerly
AG-014699). This agent has been most extensively tested
along with temezolamide in metastatic melanoma.9 A phase 1
study evaluated pharmacodynamics and pharmacokinetics
with a single dose on day 7. Evidence of activity was seen
(greater than historical controls with temozolamide), and a
phase II trial in melanoma was proposed. There is an ongoing
phase I trial of the agent along with single agent carboplatin,
carboplatin  paclitaxel, or cisplatin  pemetrexed.
CONCLUSION AND FUTURE DIRECTIONS
In conclusion, several approaches were discussed, in-
cluding tailored approaches and HSP90 inhibitors, both of
which were discussed more thoroughly during other sessions.
NOV-002, the proprietary formulation of oxidized glutathi-
one, did not reach its end point in a phase III clinical trial after
promising results in a randomized phase II trial. The most
extensive discussion covered the PARP inhibitors. These
agents are considered very promising antineoplastic agents,
and clinical trials are being aggressively pursued in lung
cancer and other types of malignancies.
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